As for Scholar Jiang, he also reached an agreement with Wu Ting. Thanks to the fourth-generation bioabsorbable stent, Wu's Pharmaceutical Company had become a key material and device partner for "Application Research of Hybrid Technology in Cardiovascular Surgery," a major project under the national "14th Five-Year Plan"!
With the endorsements from the two academicians, the heads of relevant departments from various hospitals in Qinghe City soon followed suit. After reporting to their respective hospitals, they also reached cooperation agreements with Wu's Pharmaceutical Company.
From this conference alone, Wu Ting signed orders worth 120 million!
This was a truly astonishing figure for a fledgling pharmaceutical company.
It also reflected the immense potential of Wu's Pharmaceutical Company's various commercial projects.
